Neurology · Boston area, MA
Neurology studies in Boston area, MA
116 recruiting studies have a site in the Boston area. This page includes nearby cities such as Cambridge, Brookline, Newton, Waltham.
116 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Bristol-Myers Squibb
- Location
- Newton, MA + 21 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 4
A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine
Pfizer
- Location
- Worcester, MA + 16 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms
phenox Inc.
- Location
- Boston, MA + 24 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Novartis Pharmaceuticals
- Location
- Foxborough, MA + 42 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
Dianthus Therapeutics
- Location
- Burlington, MA + 29 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
Xenon Pharmaceuticals Inc.
- Location
- Chestnut Hill, MA + 44 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 2
Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type
Teikoku Pharma USA, Inc.
- Location
- Worcester, MA + 7 other US sites
- Eligibility basics
- Any age listed
- RecruitingPhase 3
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
Alnylam Pharmaceuticals
- Location
- Boston, MA + 9 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 2
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
Lighthouse Pharmaceuticals, Inc.
- Location
- Boston, MA + 36 other US sites
- Eligibility basics
- Ages 55–80
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Bristol-Myers Squibb
- Location
- Newton, MA + 23 other US sites
- Eligibility basics
- Ages 60–85
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Hoffmann-La Roche
- Location
- Boston, MA + 52 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 3
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
Prilenia
- Location
- Boston, MA + 17 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 2
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
Appello Pharmaceuticals, Inc.
- Location
- Boston, MA + 29 other US sites
- Eligibility basics
- Ages 30–80
- RecruitingPhase 2
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Neuron23 Inc.
- Location
- Boston, MA + 43 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 2
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Immunovant Sciences GmbH
- Location
- Boston, MA + 30 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2/Phase 3
RAPA-501 Therapy for ALS
Rapa Therapeutics LLC
- Location
- Boston, MA
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
UCB Biopharma SRL
- Location
- Boston, MA + 41 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 2
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
Intra-Cellular Therapies, Inc.
- Location
- Boston, MA + 22 other US sites
- Eligibility basics
- Ages 55+
- RecruitingPhase 2
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
Eli Lilly and Company
- Location
- New Bedford, MA + 34 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)
Insmed Gene Therapy LLC
- Location
- Worcester, MA + 6 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Belmont, MA + 43 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
Novartis Pharmaceuticals
- Location
- Boston, MA + 39 other US sites
- Eligibility basics
- Ages 21–70
- RecruitingPhase 1/Phase 2
A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
AbbVie
- Location
- Watertown, MA + 10 other US sites
- Eligibility basics
- Ages 50–90
- RecruitingPhase 1/Phase 2
A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy
NaviFUS Corporation
- Location
- Boston, MA + 2 other US sites
- Eligibility basics
- Ages 18+
Who these studies look for
Most require a confirmed diagnosis; memory studies often ask for a study partner who knows you well to attend some visits.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.